<DOC>
	<DOCNO>NCT02270034</DOCNO>
	<brief_summary>This multicenter , open-label , phase Ib trial aim assess safety activity safety crizotinib ( combination radiotherapy temozolomide ) adult patient newly diagnose glioblastoma .</brief_summary>
	<brief_title>Study Evaluate Safety Activity Crizotinib With Temozolomide Radiotherapy Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1 . Ability understand willingness sign write informed consent document . 2 . Male Female ≥18 year old ≤ 70 year old 3 . Newly diagnose glioblastoma ( GB ) confirm biopsy resection 47 week registration . 4 . Patients must least 15 unstained slide 1 tissue block ( frozen paraffin embed ) available prior biopsy surgery ( archival tumor material ) . 5 . Patients must sufficient time recovery prior surgery ( least 4 week ) . 6 . Karnofsky Performance Score ( KPS ) ≥ 60 % . 7 . Adequate hematologic function : Hemoglobin ≥ 10 g/dL , Leukocytes &gt; 3,000/mcL , absolute neutrophil count ( UNL ) ≥ 1,500 cells/ul , platelet ≥ 100,000 cells/ul . 8 . Adequate liver function : Bilirubin ≤ 2 X upper limit normal ( ULN ) ; aspartate aminotrasferase ( AST ) ( SGOT ) ≤ 2.5 X ULN 9 . Creatinine within normal institutional limit creatinine clearance &gt; 60 mL/min/1.73 m2l subject creatinine level institutional normal . 10 . The effect crizotinib develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal harrier method birth control ; abstinence ; surgical sterilization ) prior study entry duration study participation least 3 month thereafter . The definition effective contraception base judgment principal investigator designate associate . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . All female patient reproductive potential must negative pregnancy test ( serum/urine ) within 2 week prior start treatment . 1 . Presence extracranial metastatic disease . 2 . Any prior radiotherapy ( RT ) chemotheraphy ( QT ) treatment . 3 . Patients must receive prior Gliadel wafer . 4 . The use enzymeinducing antiepileptic drug allow . Those patient take enzymeinducing antiepileptic drug require 7day washout period registration . 5 . Any surgery ( include minor diagnostic procedure lymph node biopsy ) within 2 week baseline disease assessment ; fully recover side effect previous procedure . 6 . Any clinically significant gastrointestinal abnormality , may impair intake , transit absorption study drug , inability take oral medication tablet form . 7 . Any psychiatric cognitive disorder would limit understand render informed consent and/or compromise compliance requirement protocol . 8 . Uncontrolled significant cardiovascular disease , include : A myocardial infarction within 12 month ; Uncontrolled angina within 6 month ; Congestive heart failure within 6 month ; Diagnosed suspect congenital long QT syndrome ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; Prolonged correct QT ( QTc ) interval preentry electrocardiogram ( &gt; 470 msec ) ; Any history second third degree heart block ( may eligible currently pacemaker ) ; Heart rate &lt; 50/minute preentry electrocardiogram ; Uncontrolled hypertension . 9 . Any patient history significant cardiovascular disease , even currently control , sign symptom suggest impaired leave ventricular function judgment investigator must screen left ventricular ejection fraction ( LVEF ) evaluation ECHO angyography ( MUGA ) . Patients LVEF measurement local institutional low limit normal le 50 % eligible . 10 . Individuals history different malignancy ineligible except follow circumstance : Individuals history malignancy eligible diseasefree least 3 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 3 year : cervical cancer situ , basal cell squamous cell carcinoma skin . Patients eligible evidence malignancy require therapy surgery within last 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>